In Conversation with Dr Gordon Sanghera

Articles From: Heptagon Capital
Website: Heptagon Capital


Equity Fund Manager

One of the first things visitors may notice when they arrive at the headquarters of Oxford Nanopore are the murals that adorn the common spaces. On one wall, there is a picture of the group Nirvana. On another, The Ramones. Blondie features on a third. When I asked my host whether the founders were music fans, I was told, sure, but the important point was that each band depicted had not only challenged prior convention but also invented something new and enduring. It is this mindset that underpins the philosophy of Oxford Nanopore. For your author, it was a privilege to recently spend an hour with the company’s co-founder, Gordon Sanghera, a luminary in the world of life sciences and innovation. Our wide-ranging conversation invoked both Darwin and Copernicus among many other topics. 

For those unaware, Oxford Nanopore was founded in 2005, with the broad ambition of “anyone being able to analyse anything anywhere.” The business listed in 2021 and is currently worth over £2bn. While many would consider what Nanopore has already achieved a marked success, the impression formed when talking with Gordon is that the business is still at a very early stage of its journey. For the team at Nanopore, there is “growing momentum” behind its approach to how DNA is sequenced (a topic we first discussed in 2012). Put simply, the business has developed a proprietary system that allows for greater levels of sequencing accuracy to be achieved at faster speeds than might be possible using more conventional systems such as those developed by industry leader, Illumina. Gordon likened the industry’s incumbents to “flat-earthers”, seeing the world only “in black and white.” By contrast, Nanopore is “bringing colour” to DNA sequencing; an approach it believes will eventually become the orthodoxy (in industry parlance, the Nanopore technique utilises ‘long reads’ on DNA versus the historic preference for ‘short reads’). 

Oxford Nanopore may well have a chance at success simply because it has always taken a different approach. Gordon arrived at his epiphany through work originally done at the time of his PhD, bringing electronics (and data) to the world of biology. He is also acutely conscious of the importance of innovation. At Nanopore, those responsible for research and development are quite explicitly separated from those involved in the manufacturing of the products, allowing the business to focus on what matters most – namely, innovation. There is also a distinct focus on creating a platform rather than applications for its platform, a key lesson absorbed from how Apple ended up becoming one of the world’s most successful companies.

What lessons can be learned from a Future Trends perspective? We have consistently advocated the Darwinian principle that the most successful businesses will be those that are most responsive to change (as opposed either to the strongest or the most intelligent, in Darwin’s summation). Oxford Nanopore embodies this approach – “we have to keep innovating through disrupting our own business”, per Gordon. With fewer than 1% of all living things on the planet – not just humans, but animals and plants too – sequenced, the runway ahead for the business is significant. As costs continue to fall, the opportunity should only increase.

Originally Posted May 23, 2023 – In conversation with Dr Gordon Sanghera

The above does not constitute investment advice and is the sole opinion of the author at the time of publication. Past performance is no guide to future performance and the value of investments and income from them can fall as well as rise.

Leave a Reply

Note that all comments are held for moderation before publishing.

Disclosure: Heptagon Capital

The document is provided for information purposes only and does not constitute investment advice or any recommendation to buy, or sell or otherwise transact in any investments. The document is not intended to be construed as investment research. The contents of this document are based upon sources of information which Heptagon Capital believes to be reliable. However, except to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to the accuracy or completeness of this document or its contents and, Heptagon Capital, its affiliate companies and its members, officers, employees, agents and advisors do not accept any liability or responsibility in respect of the information or any views expressed herein. Opinions expressed whether in general or in both on the performance of individual investments and in a wider economic context represent the views of the contributor at the time of preparation. Where this document provides forward-looking statements which are based on relevant reports, current opinions, expectations and projections, actual results could differ materially from those anticipated in such statements. All opinions and estimates included in the document are subject to change without notice and Heptagon Capital is under no obligation to update or revise information contained in the document. Furthermore, Heptagon Capital disclaims any liability for any loss, damage, costs or expenses (including direct, indirect, special and consequential) howsoever arising which any person may suffer or incur as a result of viewing or utilising any information included in this document.

The document is protected by copyright. The use of any trademarks and logos displayed in the document without Heptagon Capital’s prior written consent is strictly prohibited. Information in the document must not be published or redistributed without Heptagon Capital’s prior written consent.

Heptagon Capital LLP, 63 Brook Street, Mayfair, London W1K 4HS
tel +44 20 7070 1800
fax +44 20 7070 1881
email [email protected]

Partnership No: OC307355 Registered in England and Wales Authorised & Regulated by the Financial Conduct Authority

Disclosure: Interactive Brokers

Information posted on IBKR Campus that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from Heptagon Capital and is being posted with permission from Heptagon Capital. The views expressed in this material are solely those of the author and/or Heptagon Capital and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

In accordance with EU regulation: The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.

Any trading symbols displayed are for illustrative purposes only and are not intended to portray recommendations.